GW Pharmaceuticals Plc, which is developing a range of new cannabinoid medicines, expects European regulators to give a decision in the first half of 2010 on its application to market a drug to treat spasticity due to multiple sclerosis.
GW Pharmaceuticals Plc, which is developing a range of new cannabinoid medicines, expects European regulators to give a decision in the first half of 2010 on its application to market a drug to treat spasticity due to multiple sclerosis.